Ecog Performance Status Calculator
Score patient functional status using the Eastern Cooperative Oncology Group scale. Enter values for instant results with step-by-step formulas.
Formula
ECOG PS = Clinician-assessed functional status grade (0-5)
The ECOG Performance Status is a clinician-assessed ordinal scale from 0 (fully active) to 5 (dead). It evaluates the patient ability to perform daily activities, capacity for self-care, and proportion of time spent in bed or chair. Additional factors like weight loss percentage and symptom burden inform the comprehensive functional assessment.
Worked Examples
Example 1: ECOG 1 Patient - Clinical Trial Eligibility
Problem: A 58-year-old with stage IIIB NSCLC can perform light office work but cannot do heavy lifting or gardening. He has lost 3% body weight over 6 months. Determine ECOG status and trial eligibility.
Solution: Patient is restricted in strenuous activity but ambulatory and can do sedentary work = ECOG 1\nWeight loss 3% = Low nutritional risk\nKPS equivalent = 70-80\nClinical trial eligibility: ECOG 0-1 required for most trials = Eligible
Result: ECOG 1 (Favorable prognosis). Eligible for most clinical trials. Candidate for standard combination chemotherapy.
Example 2: ECOG 3 Patient - Treatment Limitations
Problem: A 72-year-old with metastatic pancreatic cancer is confined to a recliner most of the day, needs help with bathing and meals, and has lost 12% body weight. Assess ECOG status and treatment options.
Solution: Limited self-care, confined to bed/chair >50% of waking hours = ECOG 3\nWeight loss 12% = High nutritional risk\nKPS equivalent = 30-40\nClinical trial eligibility: Generally not eligible
Result: ECOG 3 (Poor prognosis). Best supportive care recommended. Consider palliative care referral and goals of care discussion.
Frequently Asked Questions
What is the ECOG Performance Status scale?
The ECOG (Eastern Cooperative Oncology Group) Performance Status scale is a standardized measure of a cancer patient's functional capacity and ability to perform daily activities. Developed in 1982 by the ECOG cooperative group, it uses a simple 0-5 scoring system where 0 represents fully active status and 5 represents death. The scale was designed to provide an objective, reproducible assessment that could be used across clinical trials and clinical practice. ECOG PS is one of the most important prognostic factors in oncology, influencing treatment decisions, clinical trial eligibility, and survival predictions. It is also known as the WHO Performance Status or Zubrod scale, as these systems use identical criteria.
How does ECOG score affect treatment decisions?
ECOG Performance Status profoundly influences oncology treatment planning at every stage of care. Patients with ECOG 0-1 are generally candidates for aggressive treatment including combination chemotherapy, high-dose regimens, and most clinical trials. ECOG 2 patients may receive modified or reduced-intensity treatment, often single-agent chemotherapy or targeted therapy rather than intensive combinations. Patients with ECOG 3-4 are typically recommended for best supportive care and palliative treatments, as aggressive therapy is unlikely to provide benefit and may cause significant harm. Studies consistently show that patients with poor performance status have higher treatment-related mortality and shorter survival regardless of cancer type. Performance status often overrides tumor-specific factors in determining the appropriateness of systemic therapy.
What is the relationship between ECOG and Karnofsky Performance Status?
The ECOG and Karnofsky Performance Status (KPS) scales both measure patient functional capacity but use different scoring systems. KPS uses a 0-100 scale in increments of 10, while ECOG uses a simpler 0-5 scale. The approximate equivalences are: ECOG 0 equals KPS 90-100, ECOG 1 equals KPS 70-80, ECOG 2 equals KPS 50-60, ECOG 3 equals KPS 30-40, and ECOG 4 equals KPS 10-20. The ECOG scale is more commonly used in modern clinical trials because it is simpler and has less inter-observer variability. However, KPS provides finer granularity that can be useful for detecting subtle changes in patient function over time. Both scales are validated prognostic tools and can be converted between each other for comparison purposes.
How reliable is ECOG scoring between different physicians?
Inter-observer agreement for ECOG Performance Status is moderate, with kappa values typically ranging from 0.5 to 0.7 in published studies. Agreement is highest for extreme scores (ECOG 0 and ECOG 4) where functional status is clearly defined, and lowest for intermediate scores (ECOG 1-2) where the boundary between restricted activity and inability to work can be subjective. Studies have shown that oncologists tend to rate patients as having better performance status than nurses or patients themselves. Patient self-assessment often yields higher (worse) ECOG scores compared to physician assessment. To improve reliability, many institutions use structured interviews or standardized questionnaires. Training and calibration among raters can improve agreement, and some clinical trials require assessors to document specific functional activities rather than relying solely on global impression.
Does ECOG Performance Status predict survival?
ECOG Performance Status is one of the strongest independent prognostic factors for survival across virtually all cancer types. Multiple large meta-analyses have confirmed that each unit increase in ECOG score is associated with significantly worse overall survival. For example, in advanced non-small cell lung cancer, median survival for ECOG 0 patients is approximately 12-18 months, ECOG 1 is 8-12 months, and ECOG 2 is 4-6 months with standard chemotherapy. In pancreatic cancer, the survival difference between ECOG 0-1 and ECOG 2 can be three-fold or greater. Performance status remains prognostic even after adjusting for tumor stage, histology, and treatment received. This strong prognostic value is why ECOG PS is a mandatory stratification factor in most randomized oncology clinical trials and a critical element of treatment decision-making.
How often should ECOG Performance Status be reassessed?
ECOG Performance Status should be assessed at every clinical encounter in oncology practice, typically at each visit before chemotherapy cycles. The frequency depends on the clinical context and treatment phase. During active treatment, assessment at each cycle (every 2-4 weeks) is standard practice. During surveillance or maintenance therapy, monthly or quarterly assessment is appropriate. Performance status can change rapidly, especially with disease progression or treatment toxicity, making frequent reassessment essential. A decline in ECOG score may signal disease progression before imaging changes are apparent and should prompt clinical evaluation. Conversely, improvement in ECOG score after starting effective therapy is a positive prognostic sign. Documentation of serial ECOG scores creates a functional trajectory that helps guide ongoing treatment decisions and prognostic discussions.